

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 JAN 02 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPC1 now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMFSERCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:46:43 ON 21 MAY 2008

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:47:00 ON 21 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8
DICTIONARY FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqen/stndoc/properties.html>

=> Uploading C:\Program Files\Stnexp\Queries\10-565048genA.str



```
chain nodes :  
9 10 11 12 13 14 17  
ring nodes :  
1 2 3 4 5 6 7 8  
chain bonds :  
7-10 8-9 8-17 10-11 11-12 11-13 11-14  
ring bonds :  
1-2 1-7 2-3 2-8 3-4 4-5 5-6 5-8 6-7  
exact/norm bonds :  
1-2 1-7 2-3 2-8 3-4 4-5 5-6 5-8 6-7 11-12 11-13 11-14  
exact bonds :  
7-10 8-9 8-17 10-11
```

G1:Cb,Hy,Ak


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS

L1

STR



G1 Cb, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sss full
FULL SEARCH INITIATED 18:48:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 169 TO ITERATE
```

100.0% PROCESSED 169 ITERATIONS 70 ANSWERS
SEARCH TIME: 00:00:01

12 70 SEA SSS FUL 11

=> file caplus
COST IN U.S. DOLLARS
SINCE FILE ENTRY SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 18:48:28 ON 21 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 May 2008 VOL 148 ISS 21
FILE LAST UPDATED: 20 May 2008 (20080520/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12

7 L2

=> s13 and acetylcholine

SL3 IS NOT A RECOGNIZED COMMAND


The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s 13 and acetylcholine
78230 ACETYLCHOLINE
73 ACETYLCHOLINES
78251 ACETYLCHOLINE
(ACETYLCHOLINE OR ACETYLCHOLINES)
L4 3 L3 AND ACETYLCHOLINE

=> d 14 1-3 abs ibib hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH₂, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; R3 = H, OH; X = physiol. acceptable anion], were prepared for treatment of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, 2-[3-(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1,1-bis(3-methyl-2-thienyl)ethanol (preparation given) was treated with MeBr in tert-Bu Me ether to give 61% (3-endo)-3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide.

ACCESSION NUMBER: 2007:146107 CAPLUS

DOCUMENT NUMBER: 146:229203

TITLE: Preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists.

INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 42pp.

CODEN: PIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016639	A2	20070208	WO 2006-US30153	20060802
WO 2007016639	A3	20070705		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,				

US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-704579P P 20050802

OTHER SOURCE(S): MARPAT 146:229203


IT 924646-68-4P 924646-70-8P 924646-72-0P
 924646-74-2P 924646-76-4P 924646-78-6P
 924655-67-4P 924655-70-9P 924655-72-1P
 924655-73-2P 924655-75-4P 924655-77-6P
 924655-78-7P 924655-80-1P 924655-81-2P
 924655-82-3P 924655-83-4P 924655-84-5P
 924655-85-6P 924655-89-0P 924655-90-3P
 924655-91-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of azoniabicyclooctanes as M3 muscarinic
 acetylcholine receptor antagonists)

RN 924646-68-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methyl-2-
 thiienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-70-8 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methoxyphenyl)ethyl]-
 8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● I⁻

RN 924646-72-0 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(4-methyl-3-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-74-2 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(5-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-76-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-chloro-2-thienyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-78-6 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis[5-(difluoromethyl)-2-thienyl]-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● Br⁻

RN 924655-67-4 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-fluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● I⁻

RN 924655-70-9 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-fluoro-2-methylphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● Br⁻

RN 924655-72-1 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-3-thienylethyl)-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● I⁻

RN 924655-73-2 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3,4-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924655-75-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3,5-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924655-77-6 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924655-78-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-fluoro-2-methylphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924655-80-1 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2,2-dicyclohexyl-2-hydroxyethyl)-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924655-81-2 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2,2-dicyclopentyl-2-hydroxyethyl)-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924655-82-3 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[3-(2-fluorophenyl)-2-hydroxypropyl]-2-[(2-fluorophenyl)methyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● Br⁻

RN 924655-83-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-pyridinylethyl)-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● I⁻

RN 924655-84-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(4-fluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● I⁻

RN 924655-85-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(4-chlorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● I⁻

RN 924655-89-0 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-chlorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



● I⁻

RN 924655-90-3 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(2,3-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● I⁻

RN 924655-91-4 CAPLUS


CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-(2,3-dichlorophenyl)-2-hydroxy-2-phenylethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I⁻

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH₂, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; X = pharmaceutically acceptable counterion], were prepared for treatment of


COPD, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, (endo)-3-[2,2-bis(3-hydroxyphenyl)ethenyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide was prepared from tri-Me phosphonoacetate, tropinone, MeI, and 3-methoxyphenylmagnesium bromide.

ACCESSION NUMBER: 2007:144089 CAPLUS
 DOCUMENT NUMBER: 146:229182
 TITLE: Preparation of 3-(arylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octanes as M3 muscarinic acetylcholine receptor antagonists.
 INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 35pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016650	A2	20070208	WO 2006-US30218	20060802
WO 2007016650	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2005-704578P P 20050802
 OTHER SOURCE(S): MARPAT 146:229182
 IT 924646-91-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylethenyldimethylazoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)
 RN 924646-91-3 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(2-methoxyphenyl)ethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● I⁻


IT 924646-68-4P 924646-70-8P 924646-72-0P
 924646-74-2P 924646-76-4P 924646-78-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of arylethenyldimethylazoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)

RN 924646-68-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-70-8 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methoxyphenyl)ethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● I⁻

RN 924646-72-0 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(4-methyl-3-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-74-2 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(5-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-76-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-chloro-2-thienyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 924646-78-6 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis[5-(difluoromethyl)-2-thienyl]-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
 AB Muscarinic acetylcholine receptor antagonists, e.g.,
 (3-endo)-3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-8-
 azoniabicyclo[3.2.1]octane bromide and methods of using them are provided.
 In addition a pharmaceutical composition for the treatment of muscarinic
 acetylcholinereceptor-mediated diseases comprising the above compound is
 disclosed.

ACCESSION NUMBER: 2005:99316 CAPLUS
 DOCUMENT NUMBER: 142:183475
 TITLE: Muscarinic acetylcholine receptor
 antagonists
 INVENTOR(S): Belmonte, Kristen E.; Busch-Petersen, Jakob; Laine,
 Dramane; Palovich, Michael R.
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009362	A2	20050203	WO 2004-US23041	20040716
WO 2005009362	A3	20050407		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259238	A1	20050203	AU 2004-259238	20040716
CA 2532433	A1	20050203	CA 2004-2532433	20040716
EP 1648461	A2	20060426	EP 2004-778509	20040716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1822839	A	20060823	CN 2004-80020652	20040716
BR 2004012537	A	20060919	BR 2004-12537	20040716

JP 2007525478	T 20070906	JP 2006-520387	20040716
IN 2006DN00077	A 20070824	IN 2006-DN77	20060104
MX 2006PA00663	A 20060330	MX 2006-PA663	20060117
US 20060178396	A1 20060810	US 2006-565048	20060117
NO 2006000777	A 20060411	NO 2006-777	20060217
PRIORITY APPLN. INFO.:		US 2003-487982P	P 20030717
		WO 2004-US23041	W 20040716

OTHER SOURCE(S): MARPAT 142:183475


IT 90114-71-9 102133-77-7 106655-98-5
106713-93-3 106954-22-7 834882-84-7
834882-85-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(muscarinic acetylcholine receptor antagonists)

RN 90114-71-9 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 102133-77-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 106655-98-5 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Br⁻

RN 106713-93-3 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● Br⁻

RN 106954-22-7 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-pyridinyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Br⁻

RN 834882-84-7 CAPLUS
 CN 8-Azoniabicyclo[3.2.1]octane, 3-(3-cyclohexyl-2-hydroxy-2-phenylpropyl)-

8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br⁻

RN 834882-85-8 CAPLUS


CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, (3-endo)-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 805224-99-1

CMF C23 H30 N O


Relative stereochemistry.



CM 2

CRN 16722-51-3

CMF C7 H7 O3 S



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 18:50:45 ON 21 MAY 2008